Patents by Inventor Katja HAIKE

Katja HAIKE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of substituted 2,3-dihydroimidazo[1,2-C]quinazolines for treating lymphomas
    Patent number: 10226469
    Abstract: Described herein are pharmaceutical combinations and compositions comprising a) a 2,3-dihydroimidazo[1,2-c]quinazoline compound, or a salt thereof, and b) one more additional active agents. The pharmaceutical combinations described herein may be useful for treating non-Hodgkin's lymphoma (NHL), particularly 1st line, 2nd line, relapsed, refractory, indolent or aggressive non-Hodgkin's lymphoma (NHL); follicular lymphoma (FL); chronic lymphocytic leukemia (CLL); marginal zone lymphoma (MZL); diffuse large B-cell lymphoma (DLBCL); mantle cell lymphoma (MCL); transformed lymphoma (TL); or peripheral T-cell lymphoma (PTCL).
    Type: Grant
    Filed: January 3, 2018
    Date of Patent: March 12, 2019
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Ningshu Liu, Katja Haike, Juliane Paul, Antje Margret Wengner
  • USE OF SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINES FOR TREATING LYMPHOMAS
    Publication number: 20180193349
    Abstract: Described herein are pharmaceutical combinations and compositions comprising a) a 2,3-dihydroimidazo[1,2-c]quinazoline compound, or a salt thereof, and b) one more additional active agents. The pharmaceutical combinations described herein may be useful for treating non-Hodgkin's lymphoma (NHL), particularly 1st line, 2nd line, relapsed, refractory, indolent or aggressive non-Hodgkin's lymphoma (NHL); follicular lymphoma (FL); chronic lymphocytic leukemia (CLL); marginal zone lymphoma (MZL); diffuse large B-cell lymphoma (DLBCL); mantle cell lymphoma (MCL); transformed lymphoma (TL); or peripheral T-cell lymphoma (PTCL).
    Type: Application
    Filed: January 3, 2018
    Publication date: July 12, 2018
    Applicant: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Ningshu LIU, Katja HAIKE, Juliane PAUL, Antje Margret WENGNER
  • Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for treating lymphomas
    Patent number: 9999623
    Abstract: Described herein arc methods of treating non-Hodgkin's lymphoma (NHL), wherein the non-Hodgkin's lymphoma (NHL) is selected from the group consisting of 1st line, 2nd line, relapsed, refractory, indolent or aggressive non-Hodgkin's lymphoma (NHL); follicular lymphoma (FL); chronic lymphocytic leukemia (CLL); marginal zone lymphoma (MZL); diffuse large B-cell lymphoma (DLBCL); mantle cell lymphoma (MCL); transformed lymphoma (TL); and peripheral T-cell lymphoma (PTCL). comprising administering to a patient in need thereof a 2,3-dihydroimidazo[1,2-c] quinazolinc compound, or a salt thereof.
    Type: Grant
    Filed: April 4, 2014
    Date of Patent: June 19, 2018
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Ningshu Liu, Katja Haike, Juliane Paul, Antje Margret Wengner
  • USE OF SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINES FOR TREATING LYMPHOMAS
    Publication number: 20160058770
    Abstract: —use of a 2,3-dihydroimidazo[1,2-c]quinazoline compound, or of a pharmaceutical composition containing same, as a sole active agent, or of a combination of a) said compound or a pharmaceutical composition containing said compound and b) one or more further active agents, for the preparation of a medicament for the treatment or prophylaxis of non-Hodgkin's lymphoma (NHL), particularly 1st line, 2nd line, relapsed, refractory, indolent or aggressive non-Hodgkin's lymphoma (NHL), in particular follicular lymphoma (FL), chronic lymphocytic leukaemia (CLL), marginal zone lymphoma (MZL), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), transformed lymphoma (TL), or peripheral T-cell lymphoma (PTCL); —combinations of a) said compound and b) one or more further active agents; —a pharmaceutical composition comprising said compound as a sole active agent for the treatment of non-Hodgkin's lymphoma (NHL), particularly 1st line, 2nd line, relapsed, refractory, indolent or aggressive non-Hodgkin's lympho
    Type: Application
    Filed: April 4, 2014
    Publication date: March 3, 2016
    Inventors: Ningshu LIU, Katja HAIKE, Juliane PAUL, Antje Margret WENGNER